Review: Lupus in adolescence
Identifieur interne : 000318 ( France/Analysis ); précédent : 000317; suivant : 000319Review: Lupus in adolescence
Auteurs : I. Kone-Paut [France] ; M. Piram [France] ; S. Guillaume [France] ; T. A. Tran [France]Source :
- Lupus [ 0961-2033 ] ; 2007-08.
English descriptors
- Teeft :
- Adult care, Adult patients, Anticardiolipin antibodies, Antiphospholipid, Antiphospholipid antibodies, Antiphospholipid syndrome, Arch pediatr, Arthritis, Arthritis rheum, Best pract, Cell transplantation, Childhood onset, Chronic disease, Chronic illness, Clinical change, Disease activity, Disease course, Disease damage, Disease duration, Disease exacerbations, Disease onset, Erythematosus, Gonadal function, Health care, High titres, Immunosuppressive agents, Irreversible damage, Jsle, Jsle patients, Juvenile idiopathic arthritis, Life expectancy, Lupus, Lupus anticoagulant, Lupus erythematosus, Lupus lupus, Lupus nephritis, Main causes, Major concern, Malar rash, Monoclonal antibodies, Mood swings, Mycophenolate mofetil, Organ damage, Osteoporosis, Ovarian failure, Overall prognosis, Paediatric, Pediatr, Pediatric, Physical activity, Physical changes, Psychosocial development, Relevant questions, Renal disease, Rheum, Rheumatol, Steroid, Successful transition, Syndrome, Systemic, Systemic lupus, Systemic lupus activity measure, Systemic lupus erythematosus, Systemic lupus erythematosus disease activity index, Therapeutic approaches, Weight loss, Young patient.
Abstract
Juvenile systemic lupus erythematosus (JSLE) represents 15—20% of all SLE cases. The leading presenting symptoms of JSLE are constitutional and not specific such as fatigue, headache, weight loss or mood swings. They are also encountered in healthy adolescents, which explains frequent diagnosis delay. The frequency of irreversible damage is high in JSLE and involves especially the renal, musculoskeletal and neuropsychiatric systems. Although the overall prognosis has markedly improved, thanks to earlier diagnosis and new therapeutic approaches, cardiovascular, hematological events and chronic renal failure remain severe, and constitute the main disease-related causes of death. Treatment is based on hydroxycloroquine and corticosteroids. Immunosuppressive agents must be discussed to decrease the duration of corticosteroids use. New drugs and monoclonal antibodies targeting B-cells and B-cell related cytokines are being evaluated with encouraging results. Management of JSLE has to challenge three objectives: controlling disease progression, obtaining patient's adherence to treatment, and preventing consequences of medication side effects on growth, puberty, development and fertility. Patients' quality of life and psychosocial development have also to be taken into account, as well as the organization of a successful transition from paediatric to adult care. Lupus (2007) 16, 606—612.
Url:
DOI: 10.1177/0961203307079562
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001578
- to stream Istex, to step Curation: 001578
- to stream Istex, to step Checkpoint: 000989
- to stream Main, to step Merge: 001B17
- to stream Main, to step Curation: 001B06
- to stream Main, to step Exploration: 001B06
- to stream France, to step Extraction: 000318
Links to Exploration step
ISTEX:DB244ED8ECE0108609E36C3A428F9882408CD7ABLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Review: Lupus in adolescence</title><author wicri:is="90%"><name sortKey="Kone Paut, I" sort="Kone Paut, I" uniqKey="Kone Paut I" first="I." last="Kone-Paut">I. Kone-Paut</name></author><author wicri:is="90%"><name sortKey="Piram, M" sort="Piram, M" uniqKey="Piram M" first="M." last="Piram">M. Piram</name></author><author wicri:is="90%"><name sortKey="Guillaume, S" sort="Guillaume, S" uniqKey="Guillaume S" first="S." last="Guillaume">S. Guillaume</name></author><author wicri:is="90%"><name sortKey="Tran, T A" sort="Tran, T A" uniqKey="Tran T" first="T. A." last="Tran">T. A. Tran</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB244ED8ECE0108609E36C3A428F9882408CD7AB</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1177/0961203307079562</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-Q1N6CHVB-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001578</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001578</idno><idno type="wicri:Area/Istex/Curation">001578</idno><idno type="wicri:Area/Istex/Checkpoint">000989</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000989</idno><idno type="wicri:doubleKey">0961-2033:2007:Kone Paut I:review:lupus:in</idno><idno type="wicri:Area/Main/Merge">001B17</idno><idno type="wicri:Area/Main/Curation">001B06</idno><idno type="wicri:Area/Main/Exploration">001B06</idno><idno type="wicri:Area/France/Extraction">000318</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Review: Lupus in adolescence</title><author wicri:is="90%"><name sortKey="Kone Paut, I" sort="Kone Paut, I" uniqKey="Kone Paut I" first="I." last="Kone-Paut">I. Kone-Paut</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author><author wicri:is="90%"><name sortKey="Piram, M" sort="Piram, M" uniqKey="Piram M" first="M." last="Piram">M. Piram</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Pediatrics and Pediatric Rheumatology, Hôpital de Bicêtre, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Guillaume, S" sort="Guillaume, S" uniqKey="Guillaume S" first="S." last="Guillaume">S. Guillaume</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Pediatrics and Pediatric Rheumatology, Hôpital de Bicêtre, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Tran, T A" sort="Tran, T A" uniqKey="Tran T" first="T. A." last="Tran">T. A. Tran</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Pediatrics and Pediatric Rheumatology, Hôpital de Bicêtre, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Lupus</title><idno type="ISSN">0961-2033</idno><idno type="eISSN">1477-0962</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage UK: London, England</pubPlace><date type="published" when="2007-08">2007-08</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="606">606</biblScope><biblScope unit="page" to="612">612</biblScope></imprint><idno type="ISSN">0961-2033</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-2033</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adult care</term><term>Adult patients</term><term>Anticardiolipin antibodies</term><term>Antiphospholipid</term><term>Antiphospholipid antibodies</term><term>Antiphospholipid syndrome</term><term>Arch pediatr</term><term>Arthritis</term><term>Arthritis rheum</term><term>Best pract</term><term>Cell transplantation</term><term>Childhood onset</term><term>Chronic disease</term><term>Chronic illness</term><term>Clinical change</term><term>Disease activity</term><term>Disease course</term><term>Disease damage</term><term>Disease duration</term><term>Disease exacerbations</term><term>Disease onset</term><term>Erythematosus</term><term>Gonadal function</term><term>Health care</term><term>High titres</term><term>Immunosuppressive agents</term><term>Irreversible damage</term><term>Jsle</term><term>Jsle patients</term><term>Juvenile idiopathic arthritis</term><term>Life expectancy</term><term>Lupus</term><term>Lupus anticoagulant</term><term>Lupus erythematosus</term><term>Lupus lupus</term><term>Lupus nephritis</term><term>Main causes</term><term>Major concern</term><term>Malar rash</term><term>Monoclonal antibodies</term><term>Mood swings</term><term>Mycophenolate mofetil</term><term>Organ damage</term><term>Osteoporosis</term><term>Ovarian failure</term><term>Overall prognosis</term><term>Paediatric</term><term>Pediatr</term><term>Pediatric</term><term>Physical activity</term><term>Physical changes</term><term>Psychosocial development</term><term>Relevant questions</term><term>Renal disease</term><term>Rheum</term><term>Rheumatol</term><term>Steroid</term><term>Successful transition</term><term>Syndrome</term><term>Systemic</term><term>Systemic lupus</term><term>Systemic lupus activity measure</term><term>Systemic lupus erythematosus</term><term>Systemic lupus erythematosus disease activity index</term><term>Therapeutic approaches</term><term>Weight loss</term><term>Young patient</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Juvenile systemic lupus erythematosus (JSLE) represents 15—20% of all SLE cases. The leading presenting symptoms of JSLE are constitutional and not specific such as fatigue, headache, weight loss or mood swings. They are also encountered in healthy adolescents, which explains frequent diagnosis delay. The frequency of irreversible damage is high in JSLE and involves especially the renal, musculoskeletal and neuropsychiatric systems. Although the overall prognosis has markedly improved, thanks to earlier diagnosis and new therapeutic approaches, cardiovascular, hematological events and chronic renal failure remain severe, and constitute the main disease-related causes of death. Treatment is based on hydroxycloroquine and corticosteroids. Immunosuppressive agents must be discussed to decrease the duration of corticosteroids use. New drugs and monoclonal antibodies targeting B-cells and B-cell related cytokines are being evaluated with encouraging results. Management of JSLE has to challenge three objectives: controlling disease progression, obtaining patient's adherence to treatment, and preventing consequences of medication side effects on growth, puberty, development and fertility. Patients' quality of life and psychosocial development have also to be taken into account, as well as the organization of a successful transition from paediatric to adult care. Lupus (2007) 16, 606—612.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Kone Paut, I" sort="Kone Paut, I" uniqKey="Kone Paut I" first="I." last="Kone-Paut">I. Kone-Paut</name></noRegion><name sortKey="Guillaume, S" sort="Guillaume, S" uniqKey="Guillaume S" first="S." last="Guillaume">S. Guillaume</name><name sortKey="Piram, M" sort="Piram, M" uniqKey="Piram M" first="M." last="Piram">M. Piram</name><name sortKey="Tran, T A" sort="Tran, T A" uniqKey="Tran T" first="T. A." last="Tran">T. A. Tran</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000318 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000318 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:DB244ED8ECE0108609E36C3A428F9882408CD7AB
|texte= Review: Lupus in adolescence
}}
| This area was generated with Dilib version V0.6.33. |  |